Dainippon To Buy Kyowa’s Chinese Unit For Production Facility
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma plans to buy a Chinese subsidiary of Kyowa Hakko Kirin, also of Japan. The price of the acquisition was not revealed, but is estimated at about $15.7 million. The agreement would give Dainippon control of Kyowa Hakko Pharmaceuticals, which has a production plant capable of making about 100 million doses a year, but yet to be placed into service. The deal is believed to fit Dainippon's operating style because it now exports products from Japan to China. Dainippon expects to have the Kyowa plant in operation in 2010. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.